MCE MedChemExpress

AKT-IN-17

Target:

Cat. No.: HY-149841 Molecular Formula: $C_{21}H_{21}ClN_4O_2S$

Molecular Weight: 428.94

Pathway: PI3K/Akt/mTOR

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

Akt

BIOLOGICAL ACTIVITY

Description	AKT-IN-17 is a AKt inhibitor. AKT-IN-17 inhibits AKt in A549 cells, leading to Apoptosis. AKT-IN-17 can be used in non-small
	cell lung cancer study $^{[1]}$.

IC₅₀ & Target AKt

105.88 μM (IC₅₀)

In Vitro

AKT-IN-17 exerts cytotoxic activity against A549 cells without influencing normal (L929) cells at their effective doses, with an IC_{50} 176.32 μ M^[1].

AKT-IN-17 (44.06, 88.12, and 176.23 μ M, 24 h) inhibited AKt in A549 cells with an IC $_{50}$ of 105.88 μ M $^{[1]}$. AKT-IN-17 (176.23 μ M, 24 h) induces early apoptosis of 3.26% and late apoptosis of 1.76% in A549 cells $^{[1]}$.

 $\label{eq:mce} \mbox{MCE has not independently confirmed the accuracy of these methods. They are for reference only.}$

Apoptosis Analysis^[1]

Cell Line:	A549
Concentration:	176.23 μΜ
Incubation Time:	24 h
Result:	Induced early apoptosis of 3.26% and late apoptosis of 1.76% in A549 cells

REFERENCES

[1]. Erdönmez B, et al. Design, Synthesis, and Evaluation of a New Series of Hydrazones as Small-Molecule Akt Inhibitors for NSCLC Therapy. ACS Omega. 2023 May 24;8(22):20056-20065.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA